RxDoctor Payments Data

David Pan

Cardiovascular Disease · Orange, CANPI 1912932740

Payments from drug & device makers

$54,037in general payments, 2019–2025

Across 654 payments — averaging $82.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$35K
  • Abbott$5K
  • Medtronic$2K
  • Novartis$2K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$1K
  • Amgen$1K
  • plus $9K from 35 others

What the payments were for

  • Consulting fees$3001%
  • Speaking & faculty fees$31,45058%
  • Travel & lodging$1,6513%
  • Food & beverage$20,57938%
  • Education$570%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$54,037 in reported general payments places this provider in the 85th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$144,169
Medicare patients
516
Services billed
1,397

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban300$318,456
XareltoRivaroxaban261$279,306
EntrestoSacubitril/Valsartan118$105,088
JardianceEmpagliflozin77$86,591
Repatha SureclickEvolocumab83$78,093
MultaqDronedarone Hcl31$47,183
KerendiaFinerenone20$17,664
Praluent PenAlirocumab18$14,058
VascepaIcosapent Ethyl15$12,490
Repatha SyringeEvolocumab20$10,060
Ezetimibe113$3,618
Losartan Potassium182$1,936
Metoprolol Succinate182$1,919
Atorvastatin Calcium227$1,914
Hydralazine Hcl160$1,624

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$548$318,456300 claims
Johnson & JohnsonXarelto$34,689$279,306261 claims
NovartisEntresto$1,711$105,088118 claims
Boehringer IngelheimJardiance$1,052$86,59177 claims
Sanofi-aventis U.S. LLCMultaq$704$47,18331 claims
BayerKerendia$315$17,66420 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Orange

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →